The rights to vaccine technologies designed to combat measles and pertussis will be transferred to an India-based business following a pair of recent licensing agreements to hasten affordable protection in India, China and additional nations.
Japan’s Takeda Pharmaceutical Co. Ltd. and Biological E. Ltd. (BE) of Hyperabad, India created a partnership to enable BE to produce low-cost combination vaccines to thwart diphtheria, tetanus and acellular pertussis and measles-rubella.
While Takeda has marketed such vaccines in Japan for over two decades, populations in low- and middle-income nations remain in need of protection. Under the arrangement, Takeda will transfer to BE its existing technology for bulk vaccine production, including technical, training and support services for both clinical and commercial development.
“Access to medicines is one of Takeda’s core values, and these agreements align with Takeda’s strategic goals to make high-impact contributions to global public health, either alone or through partners,” Rahul Singhvi, Takeda’s vaccine business unit chief operations officer, said. “These two agreements along with our current vaccine pipeline underscore our global commitment to address important infectious diseases across the globe.”
BE's Managing Director Mahima Datla noted previous success via franchising in developing nations, adding that “this collaboration allows us to serve additional markets and diversify our geographic presence. In the context of MR, we look forward to contributing to the measles elimination goals and protection against rubella.”